Faron Pharmaceuticals Oy (LON:FARN) Share Price Passes Below Fifty Day Moving Average - Time to Sell?

Key Points

• Faron Pharmaceuticals Oy shares fell below their 50-day moving average of GBX 207.59, trading as low as GBX 190 during Monday's trading session.
• The company's stock is currently down 2.1%, with a market capitalization of £213.83 million and a PE ratio of -707.41.
• Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for significant unmet medical needs, including its investigative immunotherapy, Clevegen (bexmarilimab).

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 207.59 ($2.81) and traded as low as GBX 190 ($2.58). Faron Pharmaceuticals Oy shares last traded at GBX 198.80 ($2.70), with a volume of 10,378 shares traded.

Faron Pharmaceuticals Oy Trading Up 2.7%

The stock has a market capitalization of £212.71 million, a price-to-earnings ratio of -703.70 and a beta of 0.36. The company's 50-day moving average is GBX 205.70 and its 200-day moving average is GBX 207.98. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.